Fasting mimicking diet reduces anti-OX40/anti PD-L1 and anti-PD-1/anti-CTLA-4 cardiovascular side effects in preclinical melanoma models

被引：0
|
作者：
Quagliariello, Vincenzo
Cortellino, Salvatore
Delfanti, Gloria
Di Mauro, Annabella
Tatangelo, Fabiana
Spagnolo, Vanessa
Visco, Euplio
Casorati, Giulia
Chiodoni, Claudia
Della Bona, Paolo
Blazevits, Olga
Ascierto, Paolo Antonio
Maurea, Nicola
Longo, Valter
机构：
[1] IRCCS Fdn G Pascale, Naples, Italy
[2] IRCCS CROB, Rionero In Vulture, Italy
[3] IRCCS S Raffaele Sci Inst, Milan, Italy
[4] Ist Nazl Tumori IRCCS Fdn G Pascale, Pathol Unit, Naples, Italy
[5] Natl Canc Inst Naples, Naples, Italy
[6] IFOM, Milan, Italy
[7] San Raffaele Inst, Milan, Italy
[8] Fdn IRCCS Isttuto Nazl Tumori, Milan, Italy
[9] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
[10] Ist Nazl Studio & Cura Tumori Fdn G Pascale IRCCS, Div Cardiol, Naples, Italy
[11] IFOM FIRC Inst Mol Oncol, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12029
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Fasting mimicking diet reduces anti-OX40/anti PD-L1 and anti-PD-1/anti-CTLA-4 cardiovascular side effects in melanoma and lung cancer models
    Cortellino, S.
    Quagliariello, V.
    Delfanti, G.
    Blazevits, O.
    Chiodoni, C.
    Maurea, N.
    Di Mauro, A.
    Tatangelo, F.
    Pisati, F.
    Shmahala, A.
    Lazzeri, S.
    Spagnolo, V.
    Visco, E.
    Tripodo, C.
    Casorati, G.
    Della Bona, P.
    Longo, V.
    ANNALS OF ONCOLOGY, 2023, 34 : S644 - S644
  • [2] Activity of Anti-PD-1 in Murine Tumor Models: Role of "Host" PD-L1 and Synergistic Effect of Anti-PD-1 and Anti-CTLA-4
    Korman, Alan
    Chen, Bing
    Wang, Changyu
    Wu, Linda
    Cardarelli, Pina
    Selby, Mark
    JOURNAL OF IMMUNOLOGY, 2007, 178
  • [3] PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
    Ellebaek, Eva
    Khan, Shawez
    Bastholt, Lars
    Schmidt, Henrik
    Haslund, Charlotte Aaquist
    Donia, Marco
    Svane, Inge Marie
    EUROPEAN JOURNAL OF CANCER, 2024, 198
  • [4] Combination immunotherapy using anti-PD-1/PD-L1 plus anti-CTLA-4 antibodies
    Reck, Martin
    ANNALS OF ONCOLOGY, 2021, 32 : S249 - S249
  • [5] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies
    Robert, Caroline
    Mateus, Christina
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308
  • [6] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
    Reddy, Swathi B.
    Possick, Jennifer D.
    Kluger, Harriet M.
    Galan, Anjela
    Han, Dale
    JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
  • [7] Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma
    Kaehler, Katharina C.
    Hassel, Jessica C.
    Heinzerling, Lucie
    Loquai, Carmen
    Moessner, Rotraut
    Ugurel, Selma
    Zimmer, Lisa
    Gutzmer, Ralf
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 (07): : 662 - 681
  • [8] Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies
    Kudo, Masatoshi
    LIVER CANCER, 2019, 8 (06) : 413 - 426
  • [9] Predictive biomarkers for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
    Subrahmanyam, Priyanka
    Dong, Zhiwan
    Gusenleitner, Daniel
    Giobbie-Hurder, Anita
    Severgnini, Mariano
    Zhou, Jun
    Manos, Michael
    Maecker, Holden
    Hodi, F. Stephen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [10] Melanoma tumor microbiome as a predictor of anti-PD-1 and anti-CTLA-4 immunotherapy response
    Uzelac, Matthew
    Li, Wei Tse
    Li, Yuxiang
    Ongkeko, Weg M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345